Inovio Pharmaceuticals (INO) Stock: Buy, Sell, or Hold?
INO - Inovio Pharmaceuticals, Inc.
$0.90
0.06 (7.16%)
▲
5d:
-9.21%
30d:
-25.71%
90d:
-6.85%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When INO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INO is currently trading at $0.90, which is considered oversold relative to its 30-day fair value range of $0.99 to $1.23.
Technical Outlook: Technically, INO is in a downtrend. Immediate support is located at $0.78, while resistance sits at $1.18. The stock is showing strong short-term momentum, up 7.2% recently.
Market Sentiment: INO scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.17 (+277.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INO is in a downtrend. Immediate support is located at $0.78, while resistance sits at $1.18. The stock is showing strong short-term momentum, up 7.2% recently.
Market Sentiment: INO scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.17 (+277.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.99 -
$1.23
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.2%)
- BULLISH: Trading 277.5% below Wall St target ($3.17)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.99 -
$1.23
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.78
Resistance Level
$1.18
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.91
Wall Street Target
$3.17
(+277.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 23, 2026 3:26 PM ET
Data refreshes hourly during market hours. Next update: 4:26 PM
Data refreshes hourly during market hours. Next update: 4:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
